Roflumilast 2 (Figure 1 and Figure 2), a second-generation PDE4 inhibitor, has been approved in the EU (in 2010) for the treatment of COPD, as well as in USA (in 2022) to treat plaque psoriasis [32,33,34]. Here, PDE4A is linked to chronic obstructive pulmonary disease.